Literature DB >> 2224434

Prostatic carcinoma: histological and immunohistological factors affecting prognosis.

R J Cohen1, G Glezerson, Z Haffejee, D Afrika.   

Abstract

Neuro-endocrine or paracrine cells of the human prostate and urethra have been identified by various methods, predominantly silver stains and immunocytochemistry. The incidence of neuro-endocrine differentiation in prostatic carcinoma has varied considerably from 10 to 100%, but has not been studied previously as an independent factor affecting prognosis. Nucleolar organiser regions (NORs) are loops of ribosomal RNA occurring in the nucleoli of cells which ultimately process RNA genes. NORs have been demonstrated by silver (Ag) staining techniques and have been studied in numerous malignant tumours. A pilot study from this laboratory has shown a distinct and significant difference in AgNOR staining between prostatic carcinoma and benign prostatic epithelial hyperplasia. A retrospective study was performed with at least 6 years' follow-up. This confirmed the presence of neuro-endocrine cells in more than half of the patients under investigation. A significant correlation between survival and the absence of neuro-endocrine cells was demonstrated. AgNOR staining was shown to be of no prognostic value.

Entities:  

Mesh:

Year:  1990        PMID: 2224434     DOI: 10.1111/j.1464-410x.1990.tb14963.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  8 in total

1.  An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.

Authors:  Joseph E Ippolito; Jian Xu; Sanjay Jain; Krista Moulder; Steven Mennerick; Jan R Crowley; R Reid Townsend; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

2.  Prostate cancer and neuroendocrine differentiation.

Authors:  M O Tan; U Karaoğlan; B Celik; O Ataoğlu; H Biri; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 3.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

4.  Do neuroendocrine cells in human prostate cancer express androgen receptor?

Authors:  J L Krijnen; P J Janssen; J A Ruizeveld de Winter; H van Krimpen; F H Schröder; T H van der Kwast
Journal:  Histochemistry       Date:  1993-11

5.  Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Authors:  Srinivas Nandana; Katharine Ellwood-Yen; Charles Sawyers; Marcia Wills; Brandy Weidow; Thomas Case; Valeri Vasioukhin; Robert Matusik
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

Review 6.  Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.

Authors:  M A Noordzij; G J van Steenbrugge; T H van der Kwast; F H Schröder
Journal:  Urol Res       Date:  1995

7.  Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides.

Authors:  Gregory J Metzger; Stephen C Dankbar; Jonathan Henriksen; Anthony E Rizzardi; Nikolaus K Rosener; Stephen C Schmechel
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

8.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.

Authors:  M E Harper; E Glynne-Jones; L Goddard; V J Thurston; K Griffiths
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.